Biogen blocking bid rejected; signs $2.4bn deal

The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pharma company fails to block €140m licence payment

23 June 2021 Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.

Americas

Biogen sues Teva over MS generic

18 March 2021 A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.